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Non-genetic drug resistance is increasingly recognised in various cancers. Molecular insights
into this process are lacking and it is unknown whether stable non-genetic resistance can be
overcome. Using single cell RNA-sequencing of paired drug naïve and resistant AML patient
samples and cellular barcoding in a unique mouse model of non-genetic resistance, here we
demonstrate that transcriptional plasticity drives stable epigenetic resistance. With a CRISPR-
Cas9 screen we identify regulators of enhancer function as important modulators of the
resistant cell state. We show that inhibition of Lsd1 (Kdm1a) is able to overcome stable
epigenetic resistance by facilitating the binding of the pioneer factor, Pu.1 and cofactor, Irf8,
to nucleate new enhancers that regulate the expression of key survival genes. This enhancer
switching results in the re-distribution of transcriptional co-activators, including Brd4, and
provides the opportunity to disable their activity and overcome epigenetic resistance.
Together these ﬁndings highlight key principles to help counteract non-genetic drug
resistance.
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Genetic clonal evolution in cancer cells has undisputedlybeen demonstrated to play a central role in mediatingresistance to a range of targeted and conventional che-
motherapies1–5. However, therapeutic resistance in the absence
of a clear genetic cause is increasingly being recognized in several
cancers including acute myeloid leukaemia (AML)6–11. Clinical
experience over many decades shows that when patients relapse
after achieving a remission to an anti-cancer therapy, re-
challenging those patients with the same therapy is invariably
futile. This is despite the fact that these patients have not been
exposed to the anti-cancer therapy for several months. Not
infrequently, genomic analyses fail to identify a genetic cause for
this stable drug resistance1–11 and even when new coding
mutations are identiﬁed, rarely have they been proven to mediate
the resistance phenotype.
The spontaneous mutation rate in AML is low and despite
the analysis of thousands of AML genomes, there is no clear
evidence of pervasive genomic instability or a hypermutator
phenotype. Several independent groups have surveyed the gen-
omes of paired pre-therapy and relapse AML cells1–4 and these
data, collected from both adult and paediatric patients, show that
acquired resistance emerges without new non-synonymous cod-
ing mutations in up to 40% of patients within some cohorts
(Fig. 1a). Interestingly, resistance in the absence of new mutations
is not signiﬁcantly associated with reduced time to relapse sug-
gesting that this is unlikely to represent an unrecognized form
of genetically driven primary resistance (Supplementary Fig. 1A).
We have previously shown in a murine AML model that
acquired therapeutic resistance to BET inhibitors, an epigenetic
therapy capable of inducing complete remissions in AML
patients12,13, emerges in the absence of new genetic mutations
from leukaemia stem cells (LSC)6. Importantly, we demonstrated
that this form of non-genetic resistance was stable, as cells that
were re-challenged after prolonged drug withdrawal remained
resistant to the therapy6. Using this unique AML model, which
recapitulates many of the features of non-genetic resistance in
human AML, we sought to establish some of the key principles
involved in this process.
Here we observe that clinical resistance to BET inhibitors can
arise in the absence of new genetic mutations. Using molecular
barcoding and single cell transcriptomics in a unique mouse
model, we show that stable non-genetic resistance to BET inhi-
bitors is acquired through dynamic transcriptional adaptation.
We identify regulators of enhancer formation as key mediators of
the resistant state and show that non-genetic therapy resistance
can be overcome by switching the enhancer dependencies of key
genes required for cell survival. As new enhancer formation
underpins non-genetic resistance to cancer therapies, these
ﬁndings provide a molecular rationale to use epigenetic drugs as
maintenance therapies to negate non-genetic transcriptional
adaptation.
Results
Clinical evidence of non-genetic resistance to BET inhibitors.
To explore the clinical relevance of our previously established
ﬁndings in a mouse model of BET inhibitor resistance, we ana-
lysed serial bone marrow samples taken from two patients
(Fig. 1b, c) enrolled on the Molibresib, Phase-1 trial in AML13.
Genomic analyses failed to reveal the emergence of any new AML
mutations or a selective advantage to pre-therapy clones at clin-
ical relapse (Supplementary Fig. 1B). Consistent with these data,
mathematical modelling of the kinetics of disease progression
reinforce that it is highly unlikely that therapeutic resistance is
due to acquired genomic evolution (Supplementary Fig. 1C, D
and Supplemetary Note 1 and Supplementary Fig. 11). In the
absence of a clear genetic cause for resistance, we sought to
explore the adaptive transcriptional responses seen in these
patients using single cell mRNA sequencing (scRNA-seq).
These data allowed us to make several key observations: as
shown in patient BET001, the transcriptional program associated
with resistance was observed in the residual cells at the time
of best clinical response. Once established, this adaptive program
was conserved and enabled the cells to expand in the context
of ongoing drug treatment resulting in clinical relapse (Fig. 1b).
Interestingly, as shown in patient BET002, even once therapy
had been withdrawn, the malignant cells that survived the
therapeutic challenge did not revert to the transcriptional state
of the pre-therapy population (Fig. 1c). Instead, they maintained
a distinct phenotypic and transcriptional proﬁle, which shared
several similarities with human LSC14,15 (Fig.1d, e, Supplemen-
tary Fig. 2A). Consistent with the likelihood of non-genetic
adaptation, these marked transcriptional changes were observed
in cells harboring the same driver mutation in the pre-therapy
and resistant state (Fig. 1f). Although these data are derived
from a limited number of patients, they recapitulate many of
the key ﬁndings derived from our AML mouse model6. Moreover,
they are also consistent with recent efforts, which have
demonstrated that resistance to conventional chemotherapy also
emerges from malignant cells with LSC properties without any
new gene mutations8.
Non-genetic resistance emerges via transcriptional adaptation.
While epigenetic resistance is seen clinically to both targeted and
conventional therapies, it remains unclear if the transcription
programs that facilitate therapeutic evasion are already present in
a pre-existing sub-population of AML cells or if they are acquired
as an adaptive response to drug pressure. Addressing this ques-
tion requires a malleable ex vivo model that recapitulates the
emergence of therapeutic resistance from LSC in the absence of
genetic evolution. Our unique model of BET inhibitor resistance
reiterates many of the clinical features described above and pro-
vides an ideal system to study the major molecular principles
involved in this process.
To understand if resistance was derived from a rare pre-
existing population of cells harboring the resistant LSC
transcription program prior to drug exposure, we DNA barcoded
drug naïve cells and regenerated the resistant population as
previously described (Fig. 2a)6. These data show that only a small
proportion of transformed cells, grown in liquid culture, have
sustained clonogenic potential in methylcellulose (Fig. 2b).
Notably, however, when increasing therapeutic pressure is
applied to cells with clonogenic potential, we found that at
least 10% of these malignant clones are able to mount an
adaptive response that enables their survival (Fig. 2b, Supple-
mentary Fig. 2B). We also coupled our cellular barcoding studies
with concurrent scRNA-seq to gain further insight into the
adaptive process. Here we performed scRNA-seq using Cel-Seq2
on the drug naïve cells with clonogenic potential as they were
serially re-plated in either vehicle or increasing concentrations
of drug, until we derived cells that were resistant to 1000 nM
of IBET (>IC90)6. Analysis of the scRNA-seq data from cells
sampled at each stage of the drug resistance process allowed us
to monitor the transcriptional trajectories of individual cells.
Pseudo-temporal ordering and t-SNE analysis of these data shows
that therapeutic evasion is due to dynamic transcriptional
adaptation rather than selection for a rare pre-existing transcrip-
tional program (Fig. 2c, Supplementary Fig. 2C). Together, these
data provide compelling evidence for dynamic transcriptional
plasticity as a major component contributing to non-genetic
therapeutic resistance.
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Epigenetic phenotypes in development and disease have been
well established to be stably inherited by daughter cells16,17, and
we have shown that these cells were unperturbed by therapeutic
re-challenge after prolonged withdrawal from drug (Supplemen-
tary Fig. 3A). To investigate this process further, both bulk RNA-
seq and scRNA-seq was performed on resistant cells withdrawn
from the drug. Principal component analysis of these data show
that the transcriptional proﬁle of the resistant cells maintained
on drug and resistant cells withdrawn from drug cluster closer
together and away from the transcriptional program of the drug
naïve cells (Supplementary Fig. 3B–C). Interestingly, although
IBET inﬂuences the expression of many genes in the cells
maintained on drug, the stable resistance program remains
unperturbed upon drug exposure (Fig. 2d). Importantly, our
scRNA-seq data in these cells shows that there is no spontaneous
reversion of even a small subset of resistant cells back to the
transcriptional program of drug naïve cells, suggesting that there
is no ﬂux between the populations, further supporting the fact
that the resistant transcriptional state is stable (Fig. 2e).
To assess the generalisability of our ﬁndings to other cancers
and therapies, we treated several patient-derived xenograft (PDX)
models of cutaneous melanoma with a BRAFV600E/MEK-
inhibitor combination until resistance developed. In these models,
we clearly observe representative examples of intrinsic and
acquired resistance (Supplementary Fig. 3D–F). In the MEL029
model, a pre-existing PI3KCA mutation drives intrinsic resistance
to combination therapy (Supplementary Fig. 3D). However, all
treated lesions from the MEL015 and MEL006 models achieve
a dramatic and durable response to this therapy18. Similar to
the well-described clinical course, we ﬁnd that continuous
MAPK-inhibition ultimately results in acquired resistance in all
cases (Supplementary Fig. 3D–F). In MEL015, we ﬁnd several
clinically prevalent acquired mutations11,19 to account for the
resistance phenotype (Supplementary Fig. 3E). Remarkably,
however, MEL006 is a representative example where stable
resistance emerges in the absence of a resistance-conferring
mutation (Supplementary Fig. 3F). These data are consistent with
the reported clinical ﬁndings in melanoma patients treated with
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MAPK inhibitors11 and highlight the fact that non-genetic
resistance is not conﬁned AML or epigenetic therapies.
Stable non-genetic resistance can be overcome. Although many
examples of non-genetic resistance to cancer therapies have been
recently described, most of these studies deal with what has been
termed a ‘drug persister’ state. Persistence is a state of reduced
growth and altered metabolism that enables the cell to have a
higher tolerance to therapeutic pressure20–25. Importantly, in
many cases, these persister cells spontaneously revert to the drug
sensitive state following drug withdrawal. Therefore, many drug
persisters can be eliminated following re-challenge after a drug
holiday20–25. These cases differ from our model and clinical
experience in AML, where resistance is not overcome by a drug
holiday. It is largely unclear if and how stable non-genetic
resistance can be overcome.
In our AML model, we have previously demonstrated that the
majority of resistant cells adopt an immature phenotype lacking
markers of myeloid differentiation including Gr1, Cd11b and
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Cd866. Therefore, to understand if epigenetic reprogramming
could reverse the stable epigenetic resistance, we performed a
focused CRISPR/Cas9 screen26 to identify the chromatin
modulators required to maintain this immature phenotype
(Fig. 3a, Supplementary Data 1). These data show that sgRNAs
for Mll4 (Kmt2d) and the associated complex member Utx
(Kdm6a) are enriched in Gr1− cells and consequently prevent
differentiation of the resistant population. In contrast, sgRNAs
against Lsd1 (Kdm1a) were enriched in cells that adopt a mature
Gr1+ state (Fig. 3a and Supplementary Data 1). As both the
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methyltransferase Mll4-Utx complex and demethylase Lsd1
functionally antagonize each other to regulate enhancer activity
via methylation of histone H3K4 (H3K4me1/2)27, these data
raised the possibility that enhancers may be key mediators of
the resistance phenotype. We validated the importance of Lsd1
in driving the mature phenotype using RNA interference (RNAi)
(Supplementary Fig. 4A, B) and a selective Lsd1 catalytic
inhibitor28 (Supplementary Fig. 4C).
To understand the therapeutic implications of these ﬁndings,
we treated the drug naïve and resistant cells with an Lsd1
inhibitor. Consistent with previous reports, we ﬁnd that
inhibition of Lsd1 is sufﬁcient to attenuate the growth of the
drug naïve AML population29,30, however it had little effect on
the growth of the resistant cells (Fig. 3b, c). Remarkably, we noted
that although Lsd1 inhibition is ineffective at reducing the growth
of the resistant cells, it restored their sensitivity to BET inhibition
(Fig. 3d). To further assess the relevance of these ﬁndings in vivo,
we serially passaged drug naïve leukaemia cells in mice with
therapy to increase their refractoriness to BET inhibition6. As a
control, we similarly passaged a matched population of AML
cells without drug exposure in vivo. In accordance with published
data, Lsd1 inhibition (LSD1i) was effective in extending survival
in mice transplanted with drug naïve AML cells29,30 (Supple-
mentary Fig. 4D). However, in line with our data ex vivo, we
found that LSD1i was largely ineffective against the in vivo drug
adapted cells but it was able to re-instate the in vivo sensitivity to
BET inhibition (Fig. 3e). Importantly, the resensitisation to BET
inhibition in vitro is not due to an immediate response to
combination therapy, instead it is a time-dependent process that
requires several days to be effective (Fig. 3f, g and Supplementary
Fig. 4E). Consistent with these ﬁndings, there is little evidence
of synergy with the combination of Lsd1 and BET inhibitors in a
broad range of human AML cells (Supplementary Fig. 4F).
Together these ﬁndings suggest that LSD1i reinstates sensitivity
to BET inhibition through a time-dependent modulation of the
resistant cells.
LSD1i restores sensitivity to IBET via new enhancer formation.
Consistent with the immunophenotypic changes induced by
LSD1i treatment, the global transcriptome analyses of the resis-
tant cells following LSD1i treatment showed an increased
expression of a myeloid differentiation program and down-
regulation of the LSC signature (Supplementary Fig. 5A, B).
Notably however, although the resensitised cells are immuno-
phenotypically similar to the drug naïve population, the overall
transcriptional program of these cells was quite distinct, sug-
gesting that LSD1i treatment did not simply result in the
restoration of the transcriptional program of the drug naïve cells
(Supplementary Fig. 5C). Therefore, we investigated whether the
speciﬁc gene expression changes associated with resistance to
IBET were reversed by LSD1i treatment. These analyses showed
that very few of the gene expression changes associated with IBET
resistance, including the previously described the Wnt/β-catenin
signature6, were reversed by LSD1i (Supplementary Fig. 5D, E).
Similarly, although treatment of the resistant cells with LSD1i
led to substantial gene-expression changes, few of these genes
were responsive to IBET and gene ontology analyses did not
reveal any signiﬁcant pathway that accounted for the renewed
sensitivity to IBET following LSD1i treatment (Supplementary
Fig. 5F). Together, these data demonstrate that resensitisation
following LSD1i treatment could not be explained by a reversion
of the transcriptional program associated with resistance.
We and others have shown that treatment of drug naïve cells
with BET inhibitors results in the potent and rapid repression of a
set of broadly expressed genes such as Myc, Bcl2 and Cdk6 that
are essential for the survival of cancer cells (Fig. 4a)31–34. In the
resistant cells, the expression of these genes is unaffected by
IBET (Fig. 4a) and interestingly, our scRNA-seq data show that
these genes are sustained in expression throughout the adaptive
response to IBET (Supplementary Fig. 6A). Consistent with
the lack of efﬁcacy of Lsd1 inhibition in the resistant cells, the
expression of this set of genes is unaltered by Lsd1 inhibitor
treatment (Fig. 4a). Surprisingly however, we found that although
Lsd1 inhibition does not affect their expression, it re-instates the
ability of BET inhibitors to repress this set of broadly expressed
essential genes, explaining why Lsd1 inhibition is able to overcome
the resistance phenotype (Fig. 4a and Supplementary Fig. 6B–C).
As our CRISPR screen suggested that regulation of enhancers
appeared to be a central process required for resensitisation, we
performed ATAC-seq to assess differential chromatin accessi-
bility sites in the drug naïve cells, and resistant cells before and
after LSD1i treatment. Although, LSD1i treatment resulted in
widespread changes in chromatin accessibility, we focused our
attention around the set of genes repressed by BET inhibition in
the drug naïve cells, as these genes are key to cancer cell survival
and their responsiveness to BET inhibitor is reinstated in resistant
cells pretreated with LSD1i (Fig. 4a). Around these genes, Lsd1
inhibition resulted in the formation of entirely new putative
cis-regulatory elements that are not present in the drug naïve
or resistant population (Fig. 4b). These new sites of increased
chromatin accessibility contain the hallmark chromatin mod-
iﬁcations of active enhancers including H3K4me1/2 and
H3K27ac (Fig. 4b, Supplementary Fig. 7A). Interestingly, we
noted that following Lsd1 inhibition, Brd4 and its associated co-
factor Med1 were redistributed from the enhancers present in the
resistant cells to these newly formed enhancers (Fig. 4c, d). Using
Click-seq35, which identiﬁes regions of the genome where Brd4 is
bound via its bromodomains and hence predicts responsiveness
to BET inhibition; we demonstrated that the increased Brd4
occupancy at these new enhancers is bromodomain dependent
(Supplementary Fig. 7B). Consequently, Brd4 is displaced from
these loci with IBET treatment, resulting in the renewed
Fig. 3 Inhibition of Lsd1 overcomes stable drug resistance in vitro and in vivo. a Epigenetic protein domain-focused CRISPR-Cas9 screen designed to identify
epigenetic proteins that sustain the immature Gr1- resistant immunophenotype. Gr1+ cells were enriched by FACS 7 days after sgRNA transduction. GR1−
enrichment was determined by the depletion of guides in the GR1+ population. Epigenetic proteins that regulate the enhancer modiﬁcation H3K4me1/2
are highlighted in red. b Proliferation assay of drug naïve and (c) drug resistant cells treated with DMSO, IBET (1000 nM) or GSK-LSD1 (500 nM). Error
bars represent S.E.M of 3 cell culture replicates. Representative of 3 biological replicates. d Proliferation assay of drug resistant cells pre-treated for 6 days
with GSK-LSD1 (500 nM) followed by treatment with DMSO or IBET (1000 nM). Error bars represent S.E.M of 3 cell culture replicates. Representative of 3
biological replicates. e Kaplan–Meier curve of vehicle and drug treated mice transplanted with MLL-AF9 leukaemic cells serially re-transplanted (4
generations) in the presence of IBET treatment (20mg/kg) to enrich for IBET-resistant leukaemia. n= 6 mice per group. Dotted line indicates the start of
treatment. Dosing was performed by IP injection once a day at 20mg/kg for IBET-151 and/or 0.5 mg/kg for GSK-LSD1. Log rank (Mantel-Cox) for DMSO
versus LSD1i+ IBET: p < 0.002, IBET versus LSD1i+ IBET: p < 0.002 and LSD1i versus LSD1i+ IBET: p < 0.002. f Flow cytometry analysis of Gr1 surface
expression after treatment of drug resistant cells with GSK-LSD1i (500 nM) for the indicated durations. g Dose–response assay (IC50) to IBET of drug
naïve, resistant cells and resistant cells pre-treated with GSK-LSD1i (500 nM) for either 1 or 6 days. Error bars represent S.E.M of 4 cell culture replicates
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repression of this critical broadly expressed set of genes (Fig. 4a
and Supplementary Fig. 7C).
Differentiation is not sufﬁcient for resensitization. Although
Lsd1 inhibition results in the formation of new enhancers around
these broadly expressed genes required to maintain the prolifera-
tion and survival of the cancer cells, the transcriptional output of
these genes remains stable (Fig. 4a, b). These intriguing ﬁndings
are consistent with a form of enhancer switching36,37, which has
been proposed to maintain the expression of important broadly
a
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expressed genes throughout development, to cater for changes in
the speciﬁc transcription factor repertoire (Supplementary
Fig. 8A). A key feature of enhancer elements is their ability to
provide sequence speciﬁc binding platforms for the coordinated
function of transcription factors27,38. Therefore, to explore the
underlying basis for the speciﬁc regulation of these new enhancers,
we asked which transcription factor binding sites were most sig-
niﬁcantly enriched at the new enhancers formed after LSD1i
treatment. The most signiﬁcant transcription factor motifs were a
Pu.1 motif and a composite EICE motif involving the lineage
deﬁning pioneer factor Pu.1 and the transcription co-factor Irf8
(Fig. 4e)39. Although rarely mutated in AML, the functional
activity of Pu.1 is perturbed by several key oncogenic drivers of
AML, including AML1-ETO, PML-RARA and MLL-fusion pro-
teins39–42. Consistent with recent reports, we found that Lsd1
inhibition results in widespread increased binding of Pu.130, but
importantly and in agreement with the in silico prediction, we
observed that co-occupancy of Pu.1 and Irf8 is far more restricted
(Supplementary Fig. 8B) and occurs at the newly formed enhan-
cers that are associated with genes critical to the resensitisation
process (Fig. 4f, g).
To investigate the role of Pu.1 in mediating the enhancer
switching that resensitises the resistant cells to BET inhibition, we
used two independent shRNA’s to deplete Pu.1 in the resistant
cells (Supplementary Fig. 8C). These data showed that following
knockdown of Pu.1, Lsd1 inhibition failed to differentiate and
resensitise the resistant cells (Fig. 5a, b, Supplementary Fig. 8D,
E). While the expression of Pu.1 is unaltered by Lsd1 inhibition
(Fig. 5e), this treatment displaces Lsd1 from the Irf8 locus leading
to marked upregulation of Irf8 (Fig. 5f and Supplementary
Fig. 9A). To explore the importance of Irf8, we knocked down
this factor and treated the resistant cells with Lsd1 inhibitor
(Supplementary Fig 9B). Here we found that although Irf8
depletion failed to prevent Lsd1 inhibitor induced myeloid
differentiation, resensitisation was abrogated (Fig. 5c, d and
Supplementary Fig 9C, D). In support of this ﬁnding, treatment
with ATRA fails to resensitise the cells, despite inducing a more
differentiated phenotype (Supplementary Fig. 9E, F).
The resensitisation of the resistant cells following Lsd1
treatment is accompanied by the following two major features:
(i) the induction of gene expression changes resulting in myeloid
differentiation and (ii) the formation of new enhancers. To
experimentally dissect the contribution of each of these to the
process of resensitisation, we performed RNA-seq on Irf8
depleted resistant cells treated with LSD1i. These data showed
that the LSD1i-mediated gene expression changes still occur in
the context of Irf8 depletion (Fig. 5g–i and Supplementary
Fig. 9G). Consistent with this ﬁnding, the LSD1i induced
transcriptional changes appear to be the result of direct de-
repression of Lsd1 target genes and do not require the Irf8
dependent new enhancers (Supplementary Fig. 10A–D). As Irf8-
depleted cells remain resistant to IBET (Fig. 5d), this experiment
suggests that the immunophenotypic and transcriptional changes
associated with LSD1i mediated differentiation are not sufﬁcient
to drive resensitisation of the resistant cells. In contrast to the
gene expression changes, depletion of Irf8 is critical for the
formation of new enhancers associated with Lsd1 inhibition
(Fig. 5j) and the associated resensitisation (Fig. 5d), indicating
that it is the enhancer remodeling associated with Lsd1 inhibition
that is primarily responsible for resensitisation.
Pu.1 requires Irf8 to form enhancers during resensitisation.
Pioneer transcription factors are able to engage nucleosomal
DNA to establish new enhancers and Pu.1 has previously been
demonstrated to actively initiate the de novo formation of
enhancers43. To understand the precise order of events that
orchestrate the development of the new enhancers following Lsd1
inhibition, we ﬁrst explored the consequences of Pu.1 depletion
on enhancer formation. These data show that reduction of Pu.1
abrogates the increased chromatin accessibility and subsequent
H3K4me1/2 and H3K27ac suggesting that Pu.1 is the initiating
event of new enhancer formation (Fig. 6a, b and Supplementary
Fig 10E–G). Consistent with the recent reports of genome-wide
motif scanning by pioneer factors44,45, we see low-level enrich-
ment of Pu.1 at enhancers that become activated upon Lsd1
inhibition (Fig. 6c). However, this low afﬁnity binding is not
sustained in the absence of the cofactor, Irf8, which is required to
stabilize Pu.1 at chromatin (Fig. 6d). Interestingly, Irf8 over-
expression is insufﬁcient to fully initiate new enhancer formation
and resensitisation (Supplementary Fig. 10H-J), suggesting that
nucleation of these new enhancers requires both the stabilization
of Pu.1 at chromatin and inhibition of the recursive enhancer
decommissioning by Lsd1. Following Lsd1 inhibition, Pu.1 is
stabilized by Irf8 and able to nucleate new enhancers, which are
then bound by transcriptional coactivators, including Brd4
(Fig. 6c). The re-distribution of Brd4 to the new enhancers is
required to sustain the expression of a set of broadly expressed
genes critical to the survival of the cells. As Brd4 is bound at these
new enhancers via its bromodomains (Supplementary Fig. 7B),
re-challenge with IBET is able to displace Brd4 from the new
enhancers (Supplementary Fig. 7C) and repress the transcription
of these genes (Fig. 4a). Together, these data provide a detailed
molecular understanding of the resensitisation process (Fig. 6e).
Discussion
Relapsed AML is frequently an incurable disease, highlighting the
urgent need to understand mechanisms of adaptation that result
in disease relapse after a clinical remission. A potentially under-
appreciated modality of therapeutic resistance is transcriptional
Fig. 4 New enhancer formation overcomes therapeutic resistance by reestablishing a targetable dependency. a RNA-seq heatmap displaying the response
of genes downregulated in drug naïve cells after 6 h of IBET (1000 nM) treatment. This core subset of genes underpins the functional effects of IBET that
result in the loss of viability of the drug naïve cells. Also shown here is the expression of these genes in cells stably resistant to 1000 nM of IBET and
resistant cells treated for 6 days with GSK-LSD1i (500 nM) followed by treatment with DMSO or IBET (1000 nM) for 6 h. b Heatmap of chromatin
accessibility and ChIP-seq occupancy for the speciﬁed proteins at the newly activated enhancer elements that form after 6 days GSK-LSD1i (500 nM)
treatment of the resistant cells. These new enhancer elements are within (+ /−) 50 kb of the transcriptional start site (TSS) of the genes shown in (a).
New enhancers are deﬁned by ATAC-seq peaks that show a > 4-fold increase in H3K27ac. The heatmap is centered to display 5 kb either side of the
ATAC-seq summit. c Average proﬁle of Brd4 occupancy at pre-existing and new enhancers for the genes shown in (a). Pre-existing enhancers are deﬁned
as H3K27ac peaks in the resistant cells within 50 kb of the TSS of the genes in (a). New enhancers are sites within 50 kb of the TSS of the gene that
show a > 4-fold change increase in H3K27ac after cells are treated for 6 days with GSK-LSD1i (500 nM). d Quantiﬁcation of change in Brd4 occupancy at
pre-existing and new enhancers displayed in (c). e De novo motif analysis of all newly activated enhancers (ATAC-seq peaks with > 4-fold increase in
H3K27ac) after 6 days GSK-LSD1i (500 nM) treatment. f Average proﬁle of Pu.1 and g Irf8 chromatin occupancy at the newly activated enhancer elements
shown in (b) in drug naïve, resistant and resistant cells treated for 6 days with GSK-LSD1i (500 nM)
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plasticity, whereby malignant cells adaptively rewire themselves
to evade a therapeutic challenge6,46. While there is now com-
pelling evidence for non-genomic evolution in cancers with a
low mutation frequency such as AML, other malignancies
can undergo this form of adaptive response to a range of
cancer therapies47,48. Here we have focused our studies on
stable non-genetic resistance to BET inhibitors in AML and have
established several important principles that might be applicable
to variety of malignant contexts. In contrast to many previous
studies of non-genetic resistance, our work has focused on ‘stable’
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non-genetic resistance. In AML, stable non-genetic resistance
appears to be common, as illustrated by clinical experience
with relapsed AML patients, our scRNA-seq data from the BET
inhibitor clinical trial and our in vitro model. Unlike models
of drug persistence, stable epigenetic adaptation cannot be
overcome by a drug holiday and instead requires active
cellular reprogramming. Our clinical data is derived from a
limited number of AML patients with a good partial remission
of moderate durability and it is possible that resistance
mechanisms in patients with longer remissions or in the context
of combination therapies may vary. Nevertheless, it is important
to note that the principles established here might have broader
application in other cancers and treatment contexts where there
is increasing evidence of stable non-genetic mechanisms of
resistance.
Here we show that stable non-genetic resistance is not neces-
sarily due to selection of a pre-existing clone but can evolve
through adaptive transcriptional plasticity. While this adaptive
response is accompanied by widespread transcriptional changes
and phenotypic alteration to a more immature cancer stem cell
like state, we ﬁnd overcoming resistance does not necessarily
depend on reversing the transcriptional changes associated with
the resistant state nor is phenotypic reversion through differ-
entiation sufﬁcient. Instead, our data argues that it is the com-
pensatory mechanism by which cancer cells use alternative
enhancers to sustain the expression of a small subset of broadly
expressed key survival genes, that is important and targeting this
process is the key to overcome non-genetic resistance. Intuitively,
the formation of new enhancers without a change in transcrip-
tional output seems like a surprising result; however, enhancer
switching is critical in normal development, where stem cells use
different enhancers to lineage speciﬁc cells to maintain the
expression of important broadly expressed genes such as Myc,
that are ubiquitously required for cellular homeostasis in virtually
all cells36,37. Similarly, here an inherently plastic cancer cell uses
the available pioneer factors/co-factors to nucleate different
enhancers to sustain expression of key survival genes such as
Myc. In the model we have studied, the myeloid speciﬁc factors
Pu.1/Irf8 are critical. In other cell lineages we expect other
transcription factors will be important. Our data suggests that
rather than aim to inhibit the ﬁnal transcriptional state/pathway
of a resistant cells, which is likely to be a constantly moving target
in an inherently plastic cell, it may be more effective to disable the
process of enhancer remodelling, which is the cornerstone of
non-genetic adaptation and resistance. It raises the prospect that
epigenetic therapies may be effective when incorporated into
maintenance strategies to curtail the transcriptional adaptation
via enhancer remodeling in residual malignant cells often present
at clinical remission.
Methods
Cell culture. MLL-AF9 parental, IBET sensitive (drug naïve) and IBET-resistant
cell lines were generated previously6. MLL-AF9 cell lines were grown in RPMI-
1640 supplemented with mouse IL-3 (10 ng/ml), 20% FCS, streptomycin (100ug/
ml), penicillin (100 units/ml) and glutamax, under standard culture conditions (5%
CO2, 37 °C). MLL-AF9 IBET-resistant cells were cultured with constant IBET
treatment (1000 nM, 0.1% DMSO), while MLL-AF9 IBET sensitive cells were
cultured with constant DMSO treatment (0.1%). HEK293T cells were cultured in
DMEM with 10% FCS with streptomycin (100ug/ml) and penicillin (100 units/ml)
in 10% CO2, 37 °C. Human AML cell lines (MV4;11, NOMO-1, THP-1, GF-D8,
SKM-1, KG-1 and UT-7) were grown in RPMI-1640 supplemented with 20% FCS,
streptomycin (100ug/ml), penicillin (100 units/ml) and glutamax, under standard
culture conditions (5% CO2, 37 °C). All cell lines were subjected to regular
mycoplasma testing and underwent short tandem repeat (STR) proﬁling. Human
AML cell lines were obtained from ATCC.
In vitro drug treatment. DMSO, IBET (IBET-151), LSD1i (GSK-LSD1)28 and
ATRA were dosed by direct addition to the culture media at 0.1%. Drugs were
refreshed every two days to ensure maximal activity. IBET was used at a ﬁnal
concentration of 1000 nM. LSD1i was used at a ﬁnal concentration of 500 nM.
ATRA was used at a ﬁnal concentration of 1000 nM.
Cell proliferation and dose–response assays. For dose–response assays, serial
dilutions of IBET, were further diluted in media before addition to 96-well plates
containing cells, to obtain a 0.1% DMSO ﬁnal concentration. After 72 h incubation,
resazurin was added to each well and plates were further incubated for 3 h.
Fluorescence was then read at 560 nm/590 nm on a Cytation 3 Imaging Reader
(BioTek). For proliferation assays, cells were seeded at a consistent density prior to
treatment in triplicate and treated with DMSO, IBET, LSD1i or both over the
indicated time period. Drug was refreshed at least every two days. Cell number was
calculated each day using the BD FACSverse (BD Biosciences).
Flow cytometry analyses. Flow cytometry analyses were performed on the
LSRFortessa X-20 ﬂow cytometer (BD Biosciences). Data were analyzed with
FlowJo software (Tree Star). Cell sorting was performed on a FACSAria Fusion
ﬂow sorter (BD Biosciences). The following antibodies were used for ﬂow cyto-
metry on cultured cells: AF700 anti-mouse Ly6-G/Ly6C (Gr-1) (108422, Biole-
gend), PE anti-mouse CD86 (105008, Biolegend), propridium iodide (P4864, Sigma
Aldrich), APC-Cy7 anti-mouse CD117 (105826, Biolegend).
Patient bone marrow mononuclear cells (BM-MNCs) were stained with the
following antibodies: FITC anti-human CD45 (11-9459-42, eBioscience), Biotin anti-
human CD3 (555338, BD Pharmigen), Biotin anti-human CD19 (555411, BD
Pharmigen), BV711 anti-human CD38 (563965, BD Pharmigen), APC anti-human
CD34 (555824, BD Pharmigen), PE anti-human CD90 (561970, BD Pharmigen),
PerCP-Cy5.5 anti-human CD45RA (45-0458-42, In Vitrogen) and V500 streptavidin
(BD Horizon, 561419). Propridium iodide was used to select for viable cells and anti-
mouse CompBeads (552843, BD biosciences) were used for single-stain controls.
Leukaemic blasts were identiﬁed using the CD45/SSC gating procedure and CD3/CD19
expression was used to exclude any lymphocytes. LMPP-like LSCs were identiﬁed by
CD34+CD38−CD45RA+CD90− expression as previously published49.
Chromatin immunoprecipitation sequencing (ChIP-seq). Chromatin immuno-
precipitation was performed as described previously50. Brieﬂy, for each ChIP, 20
million cells were crosslinked for 15mins with 1% formaldehyde. Crosslinked
material was sonicated to ~200–1000 bp using the Covaris Ultrasonicator e220.
Sonicated material was incubated overnight with each antibody, then incubated for 3
h with Protein A magnetic beads. Beads were washed with low and high salt wash
buffers, LiCl buffer and TE, before being eluted and decrosslinked overnight. DNA
Fig. 5 Enhancer remodeling mediated by Pu.1 and Irf8 is required for resensitisation, rather than LSD1i-mediated differentiation. a Flow cytometry of CD86
expression in the resistant cells expressing shRNA_control and shRNA_Pu.1. The shRNA expressing resistant cells were treated for 6 days with DMSO or
GSK-LSD1i (500 nM). b Proliferation assay of shRNA_control and shRNA_Pu.1 resistant cells pre-treated for 6 days with GSK-LSD1 (500 nM) followed by
treatment with DMSO or IBET (1000 nM). Error bars represent S.E.M of 3 cell culture replicates. Representative of 3 biological replicates. c Flow cytometry
of CD86 expression in shRNA_control and shRNA_Irf8 cells treated for 6 days with DMSO or GSK-LSD1i (500 nM). d Proliferation assay of shRNA_control
and shRNA_Irf8 resistant cells pre-treated for 6 days with GSK-LSD1 (500 nM) followed by treatment with DMSO or IBET (1000 nM). Error bars represent
S.E.M of 3 cell culture replicates. Representative of 3 biological replicates. e Western blot of Pu.1 levels in resistant cells and resistant cells treated for
6 days with GSK-LSD1i (500 nM). fWestern blot of Irf8 levels in resistant cells and resistant cells treated for 6 days with GSK-LSD1i (500 nM). g RNA-seq
heatmap displaying the LSD1i associated gene expression changes in shRNA_control and shRNA_Irf8 resistant cells treated for 6 days with DMSO or GSK-
LSD1i (500 nM). LSD1i-associated gene expression changes deﬁned as genes that are differentially expressed upon 6 days GSK-LSD1i (500 nM) treatment
in shRNA_control resistant cells. h Scatter-plot displaying the fold change of the LSD1i associated gene expression changes (deﬁned in g) in shRNA_control
and Irf8_shRNA1 resistant cells. i Scatter-plot displaying the fold change of the LSD1i associated gene expression changes (deﬁned in g) in shRNA_control
and Irf8_shRNA2 resistant cells. j Average proﬁle of chromatin accessibility at the newly formed Pu.1 bound enhancers in shRNA_control and Irf8_shRNA1
resistant cells treated with DMSO or GSK-LSD1i for 6 days
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was puriﬁed using Qiagen Minelute columns. All ChIP antibodies were used at ~10ug
per IP and are listed under the antibodies section. Minor modiﬁcations were made for
Lsd1 and Brd4 ChIP, including using 60 million cells and crosslinking for 20mins
with 1% formaldehyde. Sequencing libraries were prepared from eluted DNA using
Rubicon ThruPLEX DNA-seq kit. Libraries were size selected between 200–500 bps
and sequenced on the NextSeq500 using the 75 bp single-end chemistry.
ChIP-seq analysis. Reads were aligned to the mouse genome (GRCm38.78) with
BWA-mem51. Duplicate reads and reads mapping to blacklist regions or the
mitochondria were removed. Peak calling was performed with MACS252 with
default parameters. Genome-browser images of ChIP–seq data was generated by
converting the bam ﬁles from BWA to TDF ﬁles with igvtools and viewing in IGV53.
ChIP–seq coverage across selected genomic regions was calculated with BEDtools54.
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Fig. 6 Irf8 stabilises low-level Pu.1 occupancy to drive new enhancer formation. a Average proﬁle of H3K4me2 occupancy in shRNA_control and
Pu.1_shRNA1 resistant cells at sites of increased Pu.1 binding (>4-fold increase) after 6 days treatment with either DMSO or GSK-LSD1i (500 nM).
b Average proﬁle of H3K27ac occupancy in shRNA_control and Pu.1_shRNA1 resistant cells at sites of increased Pu.1 binding (>4-fold increase) after
6 days treatment with either DMSO or GSK-LSD1i (500 nM). c Heatmap of chromatin accessibility and ChIP-seq occupancy for the speciﬁed proteins at
activated Pu.1 bound enhancers in the resistant cells before and after 6 days treatment with GSK-LSD1i (500 nM). d Average proﬁle of Pu.1 occupancy at
the newly formed Pu.1 bound enhancers in shRNA_control and Irf8_shRNA1 resistant cells treated with DMSO or GSK-LSD1i for 6 days. e Schematic
diagram summarizing the divergent molecular mechanisms underpinning differentiation and re-sensitization of the resistant cells after LSD1i treatment
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New enhancer analysis. New enhancers were identiﬁed by H3K27ac peaks with >
4-fold higher read coverage after LSD1i treatment in IBET Resistant cells within 50
kb of IBET responsive genes (downregulated > 1.5 FC, p value < 0.01 with 6 h IBET
in drug naive cells). New Pu.1 enhancers were deﬁned by an increased in Pu.1
occupancy (>4-fold) in resistant cells with LSD1i treatment. New Pu.1 active
enhancers were deﬁned by an increased in Pu.1 occupancy (>4-fold) and increase
in H3K27ac ( > 4-fold) in resistant cells with LSD1i treatment. Average proﬁles and
heatmaps of ChIP–seq and ATAC-seq reads in the 5 kb around the new enhancers
were generated with ngs.plot55. Motif analysis on the new enhancers was per-
formed with MEME and CentriMo56.
Lentivirus and retrovirus production and transduction. Lentivirus was prepared
by transfecting HEK293T cells with shRNA:pVSVg:psPAX2 plasmids in a 3:2:1
ratio using PEI reagent. Retrovirus was prepared by transfecting HEK293T cells
with shRNA:gagPol:pVSVG in a 10:4:1 ratio using PEI reagent. The viral super-
natant was collected 48 h following transfection, ﬁltered through a 0.45 μm ﬁlter,
and added to cells.
Positive selection CRISPR-Cas9 screen. CRISPR-Cas9 screens were conducted
on a polyclonal population of MLL-AF9 IBET-resistant cells that had been
transduced with FUCas9Cherry (Addgene #70182). Highly positive Cas9 cells were
sorted to ensure maximal editing efﬁciency. The epigenetic domain speciﬁc sgRNA
library (~1200 guides) used in both screens was obtained through collaboration
with the Vakoc laboratory57. The sgRNA vector was ampliﬁed to maintain guide
representation. Lentivirus from the sgRNA library was prepared as described
above. Sufﬁcient MLL-AF9 IBET-resistant cells were used to maintain 5000 fold
representation at all stages of the screening process. The cells were transduced with
an appropriate volume of viral supernatant to ensure only a single guide was
present in most cells (MOI= 0.3). Transduced cells were sorted and allowed to
grow in culture for 7 days. After 7 days, differentiated cells (GR1+) were isolated
by ﬂow cytometry. The library control was also isolated at this corresponding time
point to provide a reference to determine enrichment due to positive selection. GR1
− enrichment was determined by calculating the depletion of guides in the GR1+
population relative to the library control. Genomic DNA was extracted using
DNAse blood and tissue kit (Qiagen), according to the manufacturer’s instructions.
PCR was conducted to maintain guide representation, using AmpliTaq Gold DNA
Polymerase (Thermo Fischer). PCR products were pooled and sequenced on the
NextSeq500 using 75 bp paired-end chemistry.
CRISPR-Cas9 screen analysis. Sequencing reads containing sgRNA sequences
were extracted from fastq ﬁle using the linux grep function for the vector sequence
“TTGTGGAAAGGACGAAACACCG” immediate 5′ to the sgRNA. The sequences
of the sgRNA and barcode were counted using the processAmplicons function in
edgeR58. RSA59 was used to identify the genes with sgRNA that were signiﬁcantly
changed in the selected cell populations. Plots of fold enrichment and –log P value
of the most differently expressed guide for each gene were generated with
ggplot2 in R.
Syngeneic mouse models of leukemia. Quaternary syngeneic transplantation
studies were performed with intravenous injection of 2 × 106 MLL-AF9 cells, into
C57BL/6 female mice. The cells were obtained from bone marrow or spleen of mice
that were injected with cells subjected to serial passaging (4°) in vivo in the pre-
sence of DMSO or IBET treatment, as described previously6. Brieﬂy, each gen-
eration of C57BL/6 female mice were intravenously injected with 2 × 106 MLL-AF9
cells and treated daily with either DMSO or IBET (20 mg/kg). All mice were
inspected daily and sacriﬁced upon signs of distress and disease. Cells from the
bone marrow of each generation were harvested and stored at −80 °C, until they
were injected into the subsequent generation. For the quaternary syngenic trans-
plantation experiments included in this manuscript, all mice were 6–8 weeks old at
the time of sublethal irradiation at a dose of 3.5 Gy. Treatment with vehicle, IBET,
GSK-LSD1 or both began at day 9 via IP daily. IBET was administered at 20 mg/kg/
day, and GSK-LSD1 was administered at 0.5 mg/kg/day. All mice were kept in a
pathogen-free animal facility, inspected daily and sacriﬁced upon signs of distress
and disease. All studies were conducted in accordance with the GSK Policy on the
Care, Welfare and Treatment of Laboratory Animals and were reviewed by the
Institutional Animal Care and Use Committee at GSK or were conducted under the
approval of the institutional animal ethics review board and were authorized by
the Animal Experimentation Ethics Committee (AEEC), Peter MacCallum Cancer
Centre. All mice were randomized before the commencement of experiment.
Differences in Kaplan–Meier survival curves were analysed using the log-rank
statistic.
shRNA-mediated knockdown. shRNAs targeting mouse Pu.1, Irf8 and non-
targeting control were cloned into the pHR-SIREN lentiviral vector. Kdm1a/
Lsd1 shRNAs and the respective non-targeting control were cloned into retroviral
MSCV-LMP (Open Biosystems), which has been modiﬁed to change GFP
into BFP.
qRT-PCR. RNA was extracted using the Qiagen RNeasy kit. cDNA was prepared
using SuperScript Vilo (Thermo Fischer) according to the manufacturers’
instructions. Quantitative real-time PCR was performed on the Applied Biosystems
StepOnePlus System using Fast SYBR green reagents (Thermo Fischer). Expression
levels were determined using the ΔΔCt method normalised to Gapdh or β2
microglobulin.
shRNA and primer sequences. The sequences for shRNAs and primers are
included in Supplementary Data 3.
RNA-seq. RNA was extracted using the Qiagen RNeasy kit. RNA concentration
was quantiﬁed with a NanoDrop spectrophotometer (Thermo Scientiﬁc). Libraries
were prepared using QuantSeq 3’ mRNA-seq Library Prep kit (Lexigen). Libraries
were sequenced on the NextSeq500 using the 75 bp single end chemistry.
RNA-seq analysis. Reads were aligned to the mouse genome (GRCm38.78) using
HiSAT60 and reads were assigned to genes using htseq-count61. Differential
expression was calculated using edgeR58. Genes with a false discovery rate cor-
rected for multiple testing using the method of Benjamini and Hochberg below
0.01 and a fold‐change greater than 1.5 were considered signiﬁcantly differentially
expressed. Principal component analysis was performed on the RNA-Seq data.
Gene set testing with ROAST was performed on voom-transformed RNA-seq data.
The lymphoid and myeloid differentiation gene signatures were obtained from de
Graaf et al 201662. ST_WNT_ BETA_CATENIN_PATHWAY from the GSEA
MSigDB C2 curated gene sets was used for the Wnt/B-catenin signature63. The LSC
gene signature was obtained from Somervaille et al 200964.
ATAC-seq. ATAC-seq libraries were prepared using the standard ATACseq pro-
tocol, as described previously with minor modiﬁcations65. Brieﬂy, 50000 cells were
lysed to isolate nuclei. Isolated nuclei were then tagmented for 30 mins at 37 °C.
Tagmented DNA was then ampliﬁed into the ﬁnal ATACseq libraries using KAPA
HotStart Ready Mix (2 × ) (KAPA Biosystems). Libraries were size selected from
150 to 700 bp and sequenced on the NextSeq500 using the 75 bp single- or paired-
end chemistry.
ATAC-seq analysis. Reads were aligned to the mouse genome (GRCm38.78)
with BWA-mem40. Duplicate reads and reads mapping to blacklist regions or the
mitochondria were removed. Peak calling was performed with MACS252 using
the no lambda and no model settings.
Western blot. Cells were lysed using RIPA whole cell lysis buffer and solubilized
by brief sonication. Whole cell lysates were then mixed with Laemmli buffer
and separated via SDS–PAGE. SDS-PAGE gels were then transferred to PVDF
membranes (Millipore) and incubated with primary antibodies (described below)
at 1:1000 of the supplied concentration and secondary antibody conjugated with
horseradish peroxidase at 1:10000 of the supplied concentration. Membranes were
then incubated with ECL (GE Healthcare) and detected on X-ray ﬁlm (Kodak).
Antibodies. The following antibodies were used for western blot and/or ChIP
analyses: anti-PU.1/SPI1 (sc325, Santa Cruz Biotechnology, 2258 S, Cell Signaling),
anti-KDM1/Lsd1 (ab17721, Abcam), anti-Irf8 (5628 S, Cell signaling), anti-HSP60
(sc13966, Santa Cruz Biotechnology), anti-H3K27ac (ab4729, Abcam), anti-
H3K4me1 (ab8895, Abcam), anti-H3K4me2 (ab32356, Abcam), anti-H3K4me3
(ab8580, Abcam), anti-Med1/CRSP1/Trap220 (A300-793A, Bethyl Labs), anti-
Brd4 (A301-985A100, Bethyl Labs), goat anti-rabbit IgG (656120, Invitrogen).
The concentration that each antibody was used is highlighted in the methods
section for ChIP and western blots.
Patient AML samples ethics and collection. Patient samples used for analysis
were collected as part of a study approved by the Peter MacCallum Cancer Centre
human research ethics committee (10/78). Patients described in this study were
enrolled in a phase 1 clinical study at the Peter MacCallum Cancer Centre in
patients with acute myeloid leukaemia undergoing treatment with the BET inhi-
bitor GSK525762 (14/105) (Clinical trial code: NCT01943851). All patients pro-
vided written informed consent. BM-MNCs were separated using Ficoll density
gradient. BM-MNCs were then cryopreserved at −80 °C in 90% FBS and 10%
DMSO. BM-MNCs samples from baseline, remission and relapse time points from
BET001 and baseline and relapse from BET002 were rapidly thawed in a 37 °C
water bath. Cells were then transferred to a 50 ml falcon tube and warm IMDM+
20% FBS+DNase1 (0.1 mg/mL) culture medium was added drop wise to the cells.
Cells were then washed with PBS+ 1% BSA and subsequently processed for ﬂow
cytometry.
Patient targeted amplicon sequencing. Bulk leukaemic blasts were sorted from
patients for targeted-amplicon sequencing. Targeted amplicon deep sequencing
(TS) was performed using the 48.48 Access Array™ system (Fluidigm), against a
panel of known COSMIC mutations in 54 genes recurrently mutated in MDS and
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AML as described previously66. Following ampliﬁcation, products were harvested,
tagged with sample-speciﬁc barcodes, pooled together and puriﬁed using AMPure
XP beads. All samples were analyzed in duplicate to control for PCR artifacts. The
puriﬁed libraries were then sequenced using 150 bp read length on the Illumina
MiSeq platform. Sequenced reads were mapped to the human reference genome
(version hg19) using BWA-MEM (version 0.7.12) with default parameters.
Mutations with at least 20x coverage, a minimum of 5 reads supporting the variant
and a mutant allele fraction greater than 1% were retained for further analysis.
Variants that were recurrently observed in more than 50% of the samples
(representing likely sequencing and/or PCR artifacts) and those with a high global
allele frequency (>0.4%) in the 1000 genomes database were ﬂagged and removed
from this curated list. Variants in the curated list were then annotated based on
their prognostic or functional relevance, as described previously67.
Droplet-based scRNA-seq using 10X. Approximately 6000 leukaemic blasts from
each patient sample were sorted directly into separate wells of a 96-well plate, each
containing reverse transcription (RT) master mix (50 uL RT Reagent mix, 3.8 μL
RT Primer, 2.4 μL Additive A and H2O to complete 70 μL). After sorting, the
volume of each well containing the leukemic blasts was brought to 90 μL with H2O
and 10 μL RT enzyme was added, mixed well and loaded onto separate channels of
the ChromiumTM Single-Cell A Chip. Reverse transcription, cDNA ampliﬁcation
and library preparation were performed based on the manufacturers protocol using
the Chromium Single Cell 3′ Library & Gel Bead Kit v2 (10X Genomics). Libraries
were then pooled at equimolar ratios and sequenced on the NovaSeq 6000 System
(2 × 150 PE reads).
10X analysis. The raw sequencing base calls were demultiplexed into fastq ﬁles
and counts (G1k V37) were generated following the Cell Ranger analysis pipeline
(10X Genomics). Further analysis was carried out using Cell Ranger R Kit (v2.0.0;
10X Genomics) in R (v3.5).
Single-cell FACS sorting for Cel-seq2 scRNA-seq. The MLL-AF9 drug naïve
parental cells were dosed with either 400 nM IBET or 0.1% DMSO (vehicle) for
4 days. The resistant cells were withdrawn from IBET four days prior to the
experiment. Viable single cells from each treatment group were sorted on the BD
FACSAria W, directly into pre-prepared 384-well plates that contained a mixture
of oligo (dT) primer, dNTPs and ERCC spike ins, as outlined in the Cel-seq2
protocol68. Plate alignment was veriﬁed by sorting single BD CompBeads (51-90-
9001291, BD Biosciences) coated in a solution of 5 mg/ml horseradish peroxidase
(HRP) (77332, Sigma Aldrich), into 8 empty wells containing 1.2 μl HRP substrate
(34028, Life Technologies) (well numbers A1, A2, A23,A24, P1,P2, P23, P24). A
colour change from clear to blue indicated that the bead had reached the bottom of
the well and the plate was correctly aligned69. Following the single-cell sort, plates
were frozen at −80 °C ready for Cel-seq2 library construction.
Cel-seq2 library construction. A modiﬁed version of Cel-seq2 was used to gen-
erate single cell cDNA libraries. Brieﬂy, the sorted 384-well plates were defrosted
on ice and the cells were lysed and the primers annealed at 65 °C. Primers con-
tained a 24 bp polyT stretch, a 6 bp unique molecular identiﬁer (UMI), a cell-
speciﬁc 8 bp barcode, the 5′ Illumina adaptor and a T7 promoter. Reverse tran-
scription, second strand synthesis and in vitro transcription were performed
according to the Cel-seq268 with the exception of the cDNA cleanup step prior to
IVT, whereby the volume of the Agencourt AMPure XP beads (A63880, Beckman
Coulter) was 5% of the total volume of beads used in the original protocol. Fol-
lowing IVT, the aRNA was fragmented, cleaned up and reverse transcribed with a
random hexamer primer containing the sequence complimentary to the 3’ Illumina
adaptor. Fragments containing both adaptors were selected for by PCR using
TruSeq Small RNA primers (Illumina) and cleaned up using a 0.7X bead to cDNA
ratio. The quality and concentration of the ﬁnal cDNA library was checked using a
High Sensitivity Bioanalyzer (Agilent). Libraries were pooled at equimolar ratios
and sequenced on the Illumina Nextseq.
Cel-seq2 scRNA-seq analysis. Reads from single-cell RNA-seq libraries were
processed in R and Bioconductor using the scPipe package70 to map reads to the
transcriptome, demultiplex reads to individual cells and counts reads mapping to
each gene. Low-quality cells and non-expressed genes were identiﬁed with the
scater package71 and removed prior to further analysis. Normalisation of the data
was performed using the scran package72. The tSNE algorithm was used to identify
subpopulations of cells and visualise the data73,74.
Pseudotime and tSNE analysis of resistance timecourse. Bcl2fastq (v2.20;
Illumina) was used for generating fastq ﬁles. scPipe (v1.3.8) pipeline75 was used
in R (v3.5) to process the fastq, align (G1k V37), de-multiplex and generate
counts. Monocle (v2.9)76 was used for normalization and the generation of tSNE
(for adaptive timecourse) and single cell trajectory plots using differentially
expressed gene set generated from bulk RNA-seq of MLL-AF9 IBET-resistant
cells and drug naïve MLL-AF9 cells cultured in DMSO.
Barcode library construction. A library of semi-random 60 bp barcode oligonu-
cleotide following the pattern 6(NNSWSNNWSW) was synthesised by Integrated
DNA Technologies (Coralville, IA, USA), made double stranded by PCR and
subsequently cloned into the MS2-P65-HSF1-mCHERRY backbone at the EspI
(BsmbI) site. Pooled ligations were electroporated into Endura ElectroCompetent
cells (60242-2, Lucigen) and plated onto agarose plates at an estimated complexity
of 300,000 barcodes. All colonies were harvested and puriﬁed using NuceloBond
Xtra Maxi-prep kit (740414.10, Macherey-Nagel). The barcode pool was subjected
to deep sequencing and a reference library of barcodes was generated using quality
control measures described previously77.
Barcode transduction and methylcellulose experiment. A total of 5 × 105 MLL-
AF9 drug naïve cells were infected with the barcode virus at a low MOI so that only
5–10% of cells were mCherry positive, ensuring a single integration per cell.
mCherry positive cells were sorted 72 h after transduction. A total of 3 × 103 cells
were taken from both the drug naïve and resistant populations expanded for
6 days. A total of 6 × 105 cells from each aliquot were seeded into 6 ml of
methylcellulose (MethoCult GF M3434, Stem Cell Technologies) to ensure 20-fold
representation of the original 3 × 103 barcodes. The methycellulose was supple-
mented with either DMSO or 400 nM IBET. Every 7 days, 6 × 105 cells were re-
plated in fresh methycellulose supplemented with increasing concentrations of
IBET (600, 800 and 1000 nM) or maintained in DMSO. Once the cells had been
exposed to 1000 nM of IBET, they were maintained in this concentration for a
further 4 weeks. At each timepoint, 2 × 106 cells from both biological replicates
were pelleted and frozen for subsequent genomic DNA extraction. This was per-
fomed in biological duplicate. The remaining cells from one biological replicate
were single cell sorted into 384-well plates and stored at −80 °C ready for scRNA-
seq Cel-seq 2 library construction, as described above.
Barcoding DNA barcode extraction and ampliﬁcation. Genomic DNA was
extracted from the barcoded cells using the DNeasy Blood and Tissue Kit (69504,
Qiagen). Barcodes were ampliﬁed in a 2-step PCR using Q5 High-Fidelity DNA
polymerase (M0491S, NEB), which ﬁrst ampliﬁed the barcode sequence and then
introduced the Illumina P5 and P7 adaptors and 6 bp index sequence to allow for
sample multiplexing. The sampling of sufﬁcient template coverage was ensured by
parallel reactions in the ﬁrst round of PCR. A PCR band of 288 bp was checked for
all samples on a 2% agarose gel and DNA concentration was quantiﬁed on the
Qubit. Biological replicates from all time points were pooled at equimolar ratios
and sequenced on the Illumina NextSeq 500.
Barcode analysis. Sequencing reads from barcoding experiments in fastq format
were ﬁltered to keep only those barcodes that (a) showed a correct constant region
(5′-CGGATCCTGACCATGTACGATTGACTA-3′) upstream of the barcode, (b)
showed the expected barcode pattern (up to 6 repeating units of
NNSWSNNWSW), (c) did not contain N residues, and (d) possessed an average
phred quality of 30 across the length of the barcode. True barcodes were mapped
to the reference library using bowtie v1.2.278. Only exact matches were allowed.
Barcode counts were tallied per sample and ranked by proportion. For each sample,
barcodes comprising 90% of the total dataset with a representation above 20 at the
baseline time point (i.e. the fold coverage per barcode at the beginning of the
experiment) were retained. Finally, the number of barcodes comprising 90% of
each sample was then sequentially ﬁltered such that those barcodes not present in
the subset comprising 90% of the total dataset of the previous replating were
ﬁltered out. This stringent ﬁltering, while necessary to limit technical artefacts
which may confound interpretation of the data, will remove some low-frequency
biological signal and therefore our data likely represent an underestimation of the
true number of clones in the resistant population.
Melanoma patient-derived xenografts (PDX). In collaboration with TRACE,
PDX models were established using tissue from patients undergoing surgery as part
of standard-of-care melanoma treatment at the University Hospitals KU Leuven.
Written informed consent was obtained from all patients and all procedures
involving human samples were approved by the UZ Leuven Medical Ethical
Committee (S54185/S57760/S59199) and carried out in accordance with the
principles of the Declaration of Helsinki. PDX models MEL006, MEL015 and
MEL029 were derived from a female, male and male patient respectively. All
procedures involving animals were performed in accordance with the guidelines of
the IACUC and KU Leuven and were carried out within the context of approved
project applications P147/2012, P038/2015, P098/2015 and P035/2016. Fresh
tumor tissue was collected in transport medium (RPMI1640 medium supple-
mented with penicillin/streptomycin and amphotericin B). Tumor fragments were
subsequently rinsed in phosphate-buffered saline supplemented with penicillin/
streptomycin and amphotericin B and cut into small pieces of approximately 3 ×
3 × 3 mm³. Tumor pieces were implanted subcutaneously in the interscapular fat
pad of female SCID-beige mice (Taconic). Sedation and analgesia was performed
using ketamine, medetomidine and buprenorphine. After reaching generation 4
(F4), one mouse with a tumor of 1000 mm³ was sacriﬁced. This tumor was minced
followed by dissociation using collagenase I & IV and trypsin. Cells were
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resuspended in serum-free DMEM/F12 medium and 250 000 cells were injected in
the interscapular fat pad of 8–16-week-old female NMRI nude mice (Taconic).
Pharmacological treatment of established PDXs. Mice with tumors reaching
1000 mm3 were started on the BRAF-MEK combination via daily oral gavage.
BRAF inhibitor dabrafenib and MEK inhibitor trametinib were dissolved in DMSO
at a concentration of 30 and 0.3 mg/mL respectively, aliquoted and stored at −80 °
C. Each day a fresh aliquot was thawed and diluted 1:10 with phosphate-buffered
saline. Mice were treated with a capped dose of 600–6 μg dabrafenib – trametinib
respectively in 200 μL total volume.
PDX targeted sequencing. Ampliﬁcation and sequencing primers located in
Supplementary Data 3. Genomic DNA samples were sequenced (1000x coverage)
for a selected panel of genes (Trusight26, Illumina). Additionally, alternative BRAF
splicing was determined by sanger sequencing79 and for ampliﬁcation events at the
BRAF locus, genomic DNA was isolated and quantitative PCR was performed80.
Known resistance-conferring mutations in MAP2K2 (exon 2 and 3) and AKT3
(exon 4) were detected by PCR and subsequent Sanger-sequencing.
Reporting Summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The sequencing data that support the ﬁndings of this study has been deposited into the
sequence read archive, which is hosted by the National Centre for Biotechnology
Information. The GEO accession number is GSE110901. All other relevant data
supporting the key ﬁndings of this study are available within the article and its
Supplementary Information ﬁles or from the corresponding author upon reasonable
request. The source data underlying Figs. 2e, 3g, 5e, 5f, Supplementary Fig. 4A, 4D and
10H are provided as a source data ﬁle. The remaining source data is available from the
authors upon request. A reporting summary for this Article is available as a
Supplementary Information ﬁle.
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